Fresenius Medical Care's AGM Sets Record Dividend Amid Strong Growth and Transformation

Fresenius Medical Care's Annual General Meeting: A Landmark for Shareholders

Fresenius Medical Care (FMC), recognized as the dominant provider of healthcare products and services for renal diseases globally, held its Annual General Meeting (AGM) on May 22, 2025, in Bad Homburg, Germany. At this pivotal event, shareholders marked a significant milestone as they approved a dividend of 1.44 Euros per share, representing a remarkable 21% rise compared to the previous year. This dividend not only sets a new record for the company but also underlines its robust financial performance through effective operational transformation.

During the meeting, Michael Sen, Chair of the Supervisory Board, recounted the challenges and achievements faced throughout the year. EMC has embarked on an ambitious journey to overhaul its operations, enabling it to deliver higher returns while establishing a framework for sustainable growth. He attributed the company’s successful transformation to the dedicated efforts of its 112,000 employees, emphasizing their essential role in reinstating shareholder trust.

Helen Giza, the CEO of Fresenius Medical Care AG, expressed pride in the organization's financial accomplishments during 2024, stating that the business achieved an organic revenue growth of 4%. This was further complemented by a significant 18% increase in operating income, demonstrating that the company's realignment into its two operational segments—Care Delivery and Care Enablement—was indeed productive.

The Care Delivery segment notably achieved nearly a 10% margin, while Care Enablement showcased an impressive 6.1% margin, nearly tripling its performance from the previous year. The CEO mentioned the FME25 transformation program, which has been instrumental in surpassing its initial target by aiming for 750 million Euros in savings, indicating a strong momentum heading into the new financial year.

A noteworthy highlight shared during the AGM was the FDA clearance for FMC's 5008X dialysis machine, the first of its kind approved in the U.S. for high-volume hemodiafiltration. Giza emphasized that this groundbreaking product is set to redefine the standards of care for dialysis patients across the nation, enhancing both their quality of life and healthcare outcomes.

The strong endorsement of FMC's strategies was reflected in the significant support from shareholders during the AGM. Over 96% approved the proposed dividend, further solidifying the company's commitment to rewarding its stakeholders amid continued progress. The AGM also passed measures aimed at simplifying the company's capital structure and enhancing its financial flexibility, including the authorization for potential share capital increases and the issuance of convertible bonds worth up to two billion Euros.

With 88.79% of share capital represented at the meeting, the mood was optimistic; shareholders demonstrated overwhelming support for the Management and Supervisory Boards. Their actions for the year were approved with a combined majority exceeding 99%, showcasing confidence in the current direction of the organization.

As Fresenius Medical Care moves forward, Giza affirmed confidence in achieving double-digit earnings growth for 2025, projecting margins between 11-12%. With the groundwork laid during 2024, the company stands poised to strengthen its market leadership while delivering valuable innovations in kidney care.

For those looking to gain more insights and updates on Fresenius Medical Care's operations and future endeavors, further information is available through their official website, Fresenius Medical Care.

In conclusion, Fresenius Medical Care's recent AGM has not only set a record in dividends but has also showcased the company's resilience and innovative spirit, promising substantial growth and improvements in renal healthcare worldwide. Such progress is vital for the millions of individuals relying on their services for quality care.